



BIEDX Ultrasound Breast Intervention Course 2025

ACCME Accreditation (in progress)

Date: 12th-13th July 2025

Venue: Singapore

Course Director: Dr. Niketa Chotai, Singapore

Faculty Panel:

- Dr. Niketa Chotai, Singapore
- Dr. Rameysh Danovani, Singapore
- Dr. Farida Briani Sobri, Indonesia
- Dr. Theresa Buenaflor, Philippines
- Dr. Melanie Seah, Singapore

Number of participants: 30 to 40

Preparatory material: Recorded talks (30min each)

- 1) USG Breast Overview: Indications, scanning technique - Dr. Niketa Chotai, Singapore
- 2) Breast USG appearance of normal breast and beyond - Dr. Theresa Buenaflor, Philippines
- 3) Approach to solid and cystic breast masses - Dr. Niketa Chotai, Singapore
- 4) USG guided Breast core biopsy Overview - Dr. Farida Briani, Indonesia
- 5) USG guided Breast vacuum assisted biopsy: When to do and when to avoid - Dr. Rameysh Danovani, Singapore
- 6) USG Triangulation - Dr. Theresa Buenaflor, Philippines



DAY 1: 12th July 2025, Saturday

Time	Program					Speakers
8:00 – 8:30	Registration					
8:30 – 9:00	Welcome & Introduction					Dr. Raj, BIDEX
9:00 – 9:30	Lecture: Approach to Indeterminate breast lesions (B3 lesions) – Evolving International guideline					Dr Niketa Chotai, SG
9.30 – 10:00	Lecture: USG guided core needle biopsy: Nuts and Bolt					Dr Theresa Buenaflor, PH
10:00 – 10:30	Lecture: MIS of Benign breast lesions utilizing vacuum assisted excision technology					Dr Farida, ID
10:30 – 11:00	<i>Morning Tea</i>					
11:00 – 12:00	Hands-on					
	WS 1 (CNB) IS: Dr Niketa GROUP A	WS 2 (VAB) IS: Dr Farida GROUP B	WS 3 (Wires and markers) IS: Dr Theresa GROUP C	WS 4 (VAB) IS: Dr M Seah GROUP D	WS 5 (VAE) IS: Dr Rameysh GROUP E	Each group with 6-7 participants
12:00 – 13:00	<i>Lunch</i>					
13:00 – 14:00	Panel discussion 1: B3 lesions					Moderator: Dr NC Panelist: All Faculties
14:00 – 15:00	Hands-on					
	WS 1 (CNB) IS: Dr Niketa GROUP B	WS 2 (VAB) IS: Dr Farida GROUP C	WS 3 (Wires and markers) IS: Dr Theresa GROUP D	WS 4 (VAB) IS: Dr M Seah GROUP E	WS 5 (VAE) IS: Dr Rameysh GROUP A	Each group with 6-7 participants
15:00 – 15:30	<i>Teabreak</i>					
15:30 – 16:30	Hands-on					
	WS 1 (CNB) IS: Dr Niketa GROUP C	WS 2 (VAB) IS: Dr Farida GROUP D	WS 3 (Wires and markers) IS: Dr Theresa GROUP E	WS 4 (VAB) IS: Dr M Seah GROUP A	WS 5 (VAE) IS: Dr Rameysh GROUP B	Each group with 6-7 participants
16.30 – 17:00	Quiz with gifts					Dr Niketa & Faculty
17.00	Group photo & End of Day 1					All



DAY 2: 13th July 2025, Sunday

Time	Program					Speakers
8:00 – 8:30	Registration					
8:30 – 8:55	Lecture: USG vacuum biopsy- When, why and How?					Dr. Melanie Seah, SG
8:55 – 9:20	Lecture: VAE in indeterminate breast lesions – Singapore experience					Dr. Ramyesh Danovani, SG
9:20 – 10:15	Panel discussion 2: B3 lesions					Moderator: Dr Niketa Panelist: All Faculties
10:15 – 10:30	Global development of B3 guidelines (Tea Symposium, Non-CME)					
10:30 – 11:00	Morning Tea					
11:00 – 12:00	Hands-on					Each group with 6-7 participants
	WS 1 (CNB) IS: Dr Niketa GROUP D	WS 2 (VAB) IS: Dr Farida GROUP E	WS 3 (Wires and markers) IS: Dr Theresa GROUP A	WS 4 (VAB) IS: Dr M Seah GROUP B	WS 5 (VAE) IS: Dr Rameysh GROUP C	
12:00 – 13:00	<i>Lunch</i>					
13:00 – 13:30	Lecture: Ultrasound Guided Localizations – Radiologist and Surgeon perspective (15 min each)					Dr. Niketa Chotai, SG Dr. Melanie Seah, SG
13:30 – 14:00	Lecture: Importance of breast tissue markers: Breast Radiologist's & Surgeon's Perspectives (15 min each)					Dr Theresa Buenaflor, PH Dr. Farida Briani, ID
14:00 -15:00	Hands-on					Each group with 6-7 participants
	WS 1 (CNB) IS: Dr Niketa GROUP E	WS 2 (VAB) IS: Dr Farida GROUP A	WS 3 (Wires and markers) IS: Dr Theresa GROUP B	WS 4 (VAB) IS: Dr M Seah GROUP C	WS 5 (VAE) IS: Dr Rameysh GROUP D	
15:00 – 15:30	<i>Teabreak</i>					
15:30 – 16:00	Feedback, closing, certificates and Group photo					



CONTINUING MEDICAL EDUCATION CREDIT INFORMATION

Accreditation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of American College of Surgeons and BIEDX. The American College of Surgeons is accredited by the ACCME to provide continuing medical education for physicians.

AMA PRA Category 1 Credits™

The American College of Surgeons designates this live activity for a maximum of 3.5 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ADDITIONAL CME INFORMATION

CME

Award of CME credits by ACS is based on compliance of the program with the ACCME accreditation requirements and does not imply endorsement by ACS of the content, the faculty, or the sponsor of the program.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn credit toward the CME requirements of the American Board of Surgery's Continuous Certification program.

Diplomates of the American Board of Surgery

By attending an ACS-accredited activity, you may choose to participate in the automatic transfer of your CME credits to the ABS via the ACCME. The direct automatic transfer applies to all learners who have an American College of Surgeons (ACS) profile, are Diplomates of the ABS, and have provided their ABS ID and date of birth in the ACS *MyCME* Portal on the Board Certification page.



BIDEX Pte. Ltd.
60 Paya Lebar Rd
#07-54
Singapore, 405091
contact@biedx.com | www.biedx.com

If you do not already have an American College of Surgeons (ACS) profile (Learner ID), you can create one through the [ACS New User Registration Form](#). This is a **free** offering for those who have enrolled in an ACS- Accredited educational activity. The ACS ID will grant you access to MyCME where you can track, manage, and send your CME Data to the ABS.

If you need assistance with creating an ACS Learner ID or are not certain if you already have one, please contact [Log-In Help](#).

For more information or to request assistance, contact mycme@facs.org



DISCLOSURE INFORMATION

In accordance with the ACCME Accreditation Criteria, the American College of Surgeons must ensure that anyone in a position to control the content of the educational activity (planners and speakers/authors/discussants/moderators) has disclosed all financial relationships with any commercial interest (termed by the ACCME as “ineligible companies”, defined below) held in the last 24 months (see below for definitions). Please note that first authors were required to collect and submit disclosure information on behalf all other authors/contributors, if applicable.

Ineligible Company: The ACCME defines an “ineligible company” as any entity producing, marketing, re-selling, or distributing health care goods or services used on or consumed by patients. Providers of clinical services directly to patients are NOT included in this definition.

Financial Relationships: Relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefits are usually associated with roles such as employment, management position, independent contractor (including research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other roles in which remuneration is received, or expected.

Conflict of Interest: Circumstances create a conflict of interest when an individual has an opportunity to affect CME content about products or services of an ineligible company with which he/she has a financial relationship.

The ACCME also requires that ACS manage any reported conflict and eliminate the potential for bias during the educational activity. Any conflicts noted below have been managed to our satisfaction. The disclosure information is intended to identify any commercial relationships and allow learners to form their own judgments. However, if you perceive a bias during the educational activity, please report it on the evaluation.



Speakers / Moderators / Discussants / Authors	No relevant financial relationships to Disclose	Disclosure		
		Company	Role	Received
Niketa Chotai, MD	Dr. Niketa Chotai, faculty for this educational event, has no relevant financial relationship(s) with ineligible companies to disclose.	N/A	N/A	N/A
Rameysh Danovani, MD	Dr. Rameysh Danovani, faculty for this educational event, has no relevant financial relationship(s) with ineligible companies to disclose.	N/A	N/A	N/A
Theresa Buenaflor, MD	Dr. Theresa Buenaflor, faculty for this educational event, has no relevant financial relationship(s) with ineligible companies to disclose.	N/A	N/A	N/A
Melanie Seah, MD	Dr. Melanie Seah, faculty for this educational event, has no relevant financial relationship(s) with ineligible companies to disclose.	N/A	N/A	N/A
Farida Briani, MD	Dr. Farida Briani, faculty for this educational event, has no relevant financial relationship(s) with ineligible companies to disclose.	N/A	N/A	N/A



Planning Committee	No relevant financial relationships to Disclose	Disclosure		
		Company	Role	Received
Niketa Chotai, MD	Dr. Niketa Chotai, faculty for this educational event, has no relevant financial relationship(s) with ineligible companies to disclose.	N/A	N/A	N/A
Rameysh Danovani, MD	Dr. Rameysh Danovani, faculty for this educational event, has no relevant financial relationship(s) with ineligible companies to disclose.	N/A	N/A	N/A
Theresa Buenaflor, MD	Dr. Theresa Buenaflor, faculty for this educational event, has no relevant financial relationship(s) with ineligible companies to disclose.	N/A	N/A	N/A
Melanie Seah, MD	Dr. Melanie Seah, faculty for this educational event, has no relevant financial relationship(s) with ineligible companies to disclose.	N/A	N/A	N/A
Farida Briani, MD	Dr. Farida Briani, faculty for this educational event, has no relevant financial relationship(s) with ineligible companies to disclose.	N/A	N/A	N/A



BIBLIOGRAPHIC SOURCES

1. Dee EC, Laversanne M, Bhoo-Pathy N, et al. Cancer incidence and mortality estimates in 2022 in Southeast Asia: A comparative analysis. *The Lancet Oncology*. Published online February 2025. doi:10.1016/s1470-2045(25)00017-8
2. Jackson RL, Double CR, Munro HJ, et al. Breast cancer diagnostic efficacy in a developing south-East Asian country. *Asian Pacific Journal of Cancer Prevention*. 2019;20(3):727-731. doi:10.31557/apjcp.2019.20.3.727
3. Bellini C, Nori Cucchiari J, Di Naro F, et al. Breast lesions of uncertain malignant potential (B3) and the risk of breast cancer development: A long-term follow-up study. *Cancers*. 2023;15(13):3521. doi:10.3390/cancers15133521
4. D'Archi S, Carnassale B, Sanchez AM, et al. Navigating the uncertainty of B3 breast lesions: Diagnostic challenges and Evolving Management Strategies. *Journal of Personalized Medicine*. 2025;15(1):36. doi:10.3390/jpm15010036
5. Catanzariti F, Avendano D, Cicero G, et al. High-risk lesions of the breast: Concurrent diagnostic tools and management recommendations. *Insights into Imaging*. 2021;12(1). doi:10.1186/s13244-021-01005-6
6. Versaggi SL, De Leucio A. Stereotactic and needle breast biopsy. In: *StatPearls*. Treasure Island (FL): StatPearls Publishing; 2025. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK559147/>.
7. Bick U, Trimboli RM, Athanasiou A, et al. Image-guided breast biopsy and localisation: Recommendations for information to women and referring physicians by the European Society of Breast Imaging. *Insights into Imaging*. 2020;11(1). doi:10.1186/s13244-019-0803-x
8. Alshafeiy TI, Matich A, Rochman CM, Harvey JA. Advantages and challenges of using breast biopsy markers. *Journal of Breast Imaging*. 2021;4(1):78-95. doi:10.1093/jbi/wbab052